

Cover Story
By Matthew Bin Han Ong
The FDA Molecular and Clinical Genetics Panel voted 10-0 to recommend approval of Cologuard—a noninvasive, multitarget stool DNA screening test for colorectal cancer.
In Brief


Trending Stories
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership










